11/28/2007

An FDA panel on Tuesday recommended that Roche change warning labels on influenza drug Tamiflu to include information on the death of several patients who developed psychiatric problems after treatment. The committee also suggested additional warnings about the risk of delirium, hallucinations and psychotic behavior linked to GlaxoSmithKline's Relenza. Roche said it hasn't found evidence that its drug caused such side effects but would continue to study the issue, and Glaxo also said there was no evidence of a link with its drug.

Related Summaries